TOMASZ M. BEER, MD
Osteopathic Medicine at Sam Jackson Park Rd, Portland, OR

6521608, Feb 18, 2003

Sep 21, 2000

09/647075

William D. Henner - Portland OR
Tomasz M. Beer - Portland OR

Oregon Health Science University - Portland OR

A61K 3159

514167, 514168

Treatment of hyperporliferative disorders (including tumors and psoriasis) by pulse administration of a drug (such as Vitamin D or an analog) that increases blood or tissue levels of Vitamin D. The drug is administered at a sufficient dose to have an anti-proliferative effect, but the pulsed administration of the drug avoids the development of severe symptomatic or life-threatening hypercalcemia. In particular embodiments, avoidance of hypercalcemia (as measured by serum levels of calcium above normal range) is avoided altogether. In a particular example, the drug is calcitriol administered at an oral dose of about 0. 5 mcg/kg once a week.

2010001, Jan 21, 2010

Apr 9, 2009

12/421471

Tomasz M. Beer - Portland OR, US

A61K 31/05, A61P 35/00

514733

Methods for treating prostate cancer comprising transdermally administering a therapeutically effective amount of diethylstilbesterol (DES), or a pharmaceutically acceptable salt or complex thereof, to a subject. In one embodiment, transdermally administered DES may be used to treat hot flashes in castrate prostate cancer patients. In another embodiment, transdermal DES may be administered as a therapy while avoiding testosterone surge and clinical tumor flare (for example, for treating symptomatic locally advanced prostate cancer, treating metastatic prostate cancer, or in a subject who is contraindicated for conventional therapy such as ADT therapy, particularly GnRH (gonadotropin-releasing hormone) therapy). In a further embodiment, transdermal DES may be administered to treat osteoporosis in men with prostate cancer. The transdermal DES may be used as a front line hormonal therapy or a second line hormonal therapy for treating prostate cancer.

2008006, Mar 20, 2008

Mar 26, 2007

11/691271

John CURD - Hillsborough CA, US
William HENNER - Tucson AZ, US
Tomasz BEER - Portland OR, US
Bradford GOODWIN - San Mateo CA, US
Alshad LALANI - San Francisco CA, US

A61K 31/59, A61K 38/16, A61K 39/395, A61P 7/02

424133100, 514167000, 514008000

The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so that high doses of the active vitamin D compound or the mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. The invention also relates a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof in combination with one or more other therapeutic agents.

2007003, Feb 15, 2007

Jul 7, 2006

11/482111

John Curd - Hillsborough CA, US
William Henner - Portland OR, US
Tomasz Beer - Portland OR, US
Bradford Goodwin - San Mateo CA, US

A61K 31/59, A61K 31/355

514167000, 514458000

The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so that high doses of the active vitamin D compound or the mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. The invention also relates a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof in combination with one or more other therapeutic agents.

2006001, Jan 26, 2006

Dec 30, 2004

11/027006

Tomasz Beer - Portland OR, US
Lisa Bland - Portland OR, US
Mark Garzotto - Portland OR, US
Jeri Janowsky - Portland OR, US

A61K 31/56

514182000

Disclosed are methods of treating a male subject diagnosed with cognitive dysfunction that include administering an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, to the male subject. Also disclosed is a method of improving cognitive function in a hypogonadal male subject that includes transdermally administering to the male subject a therapeutically effective amount of an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof. Further disclosed is a method of improving cognitive function in a male subject that includes administering to the male subject an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, at a dosage of about 0.025 to about 1.5 mg/day.

2003011, Jun 26, 2003

Nov 21, 2002

10/302654

William Henner - Portland OR, US
Tomasz Beer - Portland OR, US

Oregon Health & Science University

A61K031/59

514/167000

Treatment of hyperproliferative disorders (including tumors and psoriasis) by pulse administration of a drug (such as Vitamin D or an analog) that increases blood or tissue levels of Vitamin D. The drug is administered at a sufficient dose to have an anti-proliferative effect, but the pulsed administration of the drug avoids the development of severe symptomatic or life-threatening hypercalcemia. In particular embodiments, avoidance of hypercalcemia (as measured by serum levels of calcium above normal range) is avoided altogether. In a particular example, the drug is calcitriol administered at an oral dose of about 0.5 mcg/kg once a week.